Cite
MLA Citation
Hans J. Moebius et al.. “ACT‐AD: Fosgonimeton in mild‐to‐moderate Alzheimer's disease – first results of a randomized, placebo‐controlled, 26‐week Phase 2 proof‐of‐concept trial.” Alzheimer's & dementia, vol. 18, n.d., p. n/a. http://access.bl.uk/ark:/81055/vdc_100173096453.0x00001d